company background image
NVS N logo

Novartis BMV:NVS N Stock Report

Last Price

Mex$2.14k

Market Cap

Mex$4.0t

7D

0%

1Y

n/a

Updated

13 Dec, 2024

Data

Company Financials +

NVS N Stock Overview

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details

NVS N fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance5/6
Financial Health4/6
Dividends5/6

Novartis AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novartis
Historical stock prices
Current Share PriceCHF 2,138.50
52 Week HighCHF 2,237.37
52 Week LowCHF 1,540.00
Beta0.51
1 Month Change-0.51%
3 Month Changen/a
1 Year Changen/a
3 Year Change20.24%
5 Year Change19.55%
Change since IPO295.53%

Recent News & Updates

Recent updates

Shareholder Returns

NVS NMX PharmaceuticalsMX Market
7D0%-2.7%0.7%
1Yn/a-25.1%-10.1%

Return vs Industry: Insufficient data to determine how NVS N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NVS N performed against the MX Market.

Price Volatility

Is NVS N's price volatile compared to industry and market?
NVS N volatility
NVS N Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement4.0%
10% most volatile stocks in MX Market6.0%
10% least volatile stocks in MX Market2.7%

Stable Share Price: NVS N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine NVS N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199676,057Vas Narasimhanwww.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
NVS N fundamental statistics
Market capMex$3.98t
Earnings (TTM)Mex$237.65b
Revenue (TTM)Mex$1.01t

16.7x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVS N income statement (TTM)
RevenueUS$49.94b
Cost of RevenueUS$12.07b
Gross ProfitUS$37.87b
Other ExpensesUS$26.11b
EarningsUS$11.76b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)5.88
Gross Margin75.83%
Net Profit Margin23.55%
Debt/Equity Ratio69.8%

How did NVS N perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

68%

Payout Ratio